|
|
 Previous Article | Table of Contents | Next Article 
Evaluation of the inhibition by heparin and hirudin of coagulation
activation during r-tPA-induced thrombolysis
M Mirshahi, J Soria, C Soria, R Faivre, H Lu, M Courtney, C Roitsch, D Tripier and JP Caen
Institut des vaisseaux et du sang (IVS), Hopital Lariboisiere, Paris, FRG.
Thrombin bound to a fibrin clot remains active and poorly accessible to
heparin-AT III complex. During fibrinolysis, thrombin is released as
thrombin-FDP complex and is inactivated by heparin-AT III. However, as
successive fibrin layers are removed, inaccessible molecules of thrombin
are exposed at the surface of the residual clot, possibly contributing to
the occurrence during thrombolytic therapy of coagulation that is poorly
controlled by heparin. We have investigated the accessibility of
fibrin-bound thrombin to hirudin. The results clearly show that two
recombinant hirudin variants neutralize thrombin both in solution and
fibrin bound. Furthermore, we have found that in in vitro models, hirudin
present in the surrounding medium of a clot under lysis is more efficient
than heparin in preventing the activation of coagulation. This observation
suggests that hirudin may be effective in the prevention of the
rethrombotic process frequently encountered during thrombolytic therapy.
Volume 74,
Issue 3,
pp. 1025-1030,
08/15/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Hu, M. Lee, W. Campbell, R. Perez-Soler, and S. Karpatkin
Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis
Blood,
November 1, 2004;
104(9):
2746 - 2751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Weitz and H. R. Buller
Direct Thrombin Inhibitors in Acute Coronary Syndromes: Present and Future
Circulation,
February 26, 2002;
105(8):
1004 - 1011.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Griscelli, H. Li, A. Bennaceur-Griscelli, J. Soria, P. Opolon, C. Soria, M. Perricaudet, P. Yeh, and H. Lu
Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
PNAS,
May 26, 1998;
95(11):
6367 - 6372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Schwarz JR, J.-C. P. Becker, R. L. Brooks, M. J. Hursting, J. L. Joffrion, G. D. Knappenberger, T. P. Kogan, P. W. Kogan, and A. A. McKinney
State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor
Clinical and Applied Thrombosis/Hemostasis,
January 1, 1997;
3(1):
1 - 15.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. A. Prager, D. R. Abendschein, C. R. McKenzie, and P. R. Eisenberg
Role of Thrombin Compared With Factor Xa in the Procoagulant Activity of Whole Blood Clots
Circulation,
August 15, 1995;
92(4):
962 - 967.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. S. Mruk, P. Zoldhelyi, M. W.I. Webster, M. Heras, D. E. Grill, D. R. Holmes Jr, V. Fuster, and J. H. Chesebro
Does Antithrombotic Therapy Influence Residual Thrombus After Thrombolysis of Platelet-Rich Thrombus? : Effects of Recombinant Hirudin, Heparin, or Aspirin
Circulation,
February 15, 1995;
93(4):
792 - 799.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. C. Bone
Modulators of Coagulation: A Critical Appraisal of Their Role in Sepsis
Arch Intern Med,
July 1, 1992;
152(7):
1381 - 1389.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. J. Popma and E. J. Topol
Adjuncts to Thrombolysis for Myocardial Reperfusion
Ann Intern Med,
July 1, 1991;
115(1):
34 - 44.
[Abstract]
[PDF]
|
|
|
|
|
